AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01346215 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: heparin sodium
Description: 5000 UI/mL
Study NCT03064581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The educational session consisted of a one-hour small group discussion (5-10 people). Gender-specific community health educators facilitated sessions for Pacific Islander women and for their spouses/significant others that included an educational video and other materials (brochure, calendar, and resource list). The video emphasized the importance of Pap testing for Pacific Islander women, and showed men supporting their women to get tested. Women's sessions provided basic information on cervical cancer and pap testing, and ended with verbal commitments and target screening dates by women to get screened. The men's education sessions contained similar information, with supplemental information on how to provide support for their wives to get tested and exercises on showing their support.
Study NCT04304209 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total mesorectal excision
Description: total mesorectal excision after neoadjuvant treatment
Study NCT01791556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV-1 viral load testing
Study NCT05278637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81mg/day x 4 weeks, Aspirin 325mg/day x 4 weeks. or Aspirin 325mg/day x 4 weeks, Aspirin 81mg/day x 4 weeks.
Study NCT05278637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 90mg BID x 4 weeks
Study NCT00645788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro Inhale, BAYQ3939)
Description: 32.5 mg ciprofloxacin DPI corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days
Study NCT00645788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg matching placebo powder formulation twice a day for 28 days
Study NCT00645788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro Inhale, BAYQ3939)
Description: 48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
Study NCT00645788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 75 mg matching placebo powder formulation twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
Study NCT03407339 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shared Oral Care intervention
Description: One hour of teaching in oral hygiene and oral diseases to health care professionals at the intervention nursing homes.~The dentists will make an assessment of the elderly's oral hygiene at baseline, after three and six months using a mucosal and plaque score. During the six months, a dentist will be doing ward rounds at each nursing home in a specific time interval. In dialog with the resident and the healthcare professional, the dentist will present individual advice on how to perform oral care based on the resident's oral care routines, oral hygiene status, and the resident's physical and cognitive function level.
Study NCT00862108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: mg/kg dose: 0.7\~1.2mg/kg PO daily morning intake 8 weeks
Study NCT00159562 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: individual education
Description: individual sessions of psycho-education
Study NCT00159562 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group education
Description: group psycho-education in 10 weekly sessions and then a session every third month for two years
Study NCT02165176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral cannabis
Study NCT03539224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Description: DTG 50 mg tablet will be orally administered once daily with or without food upto 48 weeks
Study NCT03539224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine (3TC)
Description: Lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets. It will be orally administered once daily with or without food upto 48 weeks.
Study NCT01721980 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GLPG0974
Study NCT04294784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)
Description: Albumin-bound Paclitaxel 100 mg/m2,ivdrip,d1,d8,d15,Q28d,or Albumin-bound Paclitaxel 125-130 mg/m2,ivdrip,d1,d8,Q21d,or Albumin-bound Paclitaxel 260mg/m2,ivdrip,d1,Q21d;SHR-1210 200mg, ivdrip,d1,Q21d.
Study NCT00063999 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00063999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01775410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wolverine System to perform atherectomy
Study NCT03208400 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: virtual reality exposure
Description: one-session exposure conveyed via virtual reality technology
Study NCT03169179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit and Bupa Boost app
Description: Fitbit Charge 2™ wearable physical activity monitor and Bupa Boost health and wellbeing smartphone app. 12 weeks initial use (individual goal-setting in weeks 1-6 then social features of the app in weeks 7-12) followed by a further five months of optional use (as desired by the participant).
Study NCT04294784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin-bound Paclitaxel
Description: Albumin-bound Paclitaxel 100 mg/m2,ivdrip,d1,d8,d15,Q28d,or Albumin-bound Paclitaxel 125-130 mg/m2,ivdrip,d1,d8,Q21d,or Albumin-bound Paclitaxel 260mg/m2,ivdrip,d1,Q21d;
Study NCT04430582 — intervention group
Intervention type: OTHER
Intervention: Cognitive Assessment (not diagnostic)
Description: Cognitive testing will assess premorbid intelligence, working memory and attention, verbal memory and delayed memory, executive function, and psychomotor speed.
Study NCT00976300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day (given in two divided doses) for 9 months followed by gradually decreasing dose of cyclosporine (3.75-1.25 mg/kg/day) within the next 9 months. The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
Study NCT00976300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals). The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
Study NCT03673228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Relapse Prevention Intervention
Description: This intervention consists of 4 components:~1. Visit Prior to Discharge: counselor from research team will visit patient at hospital bedside to provide counseling~2. Follow up calls after discharge: 6 proactive counseling calls and initiate unlimited reactive calls to their counselor, at days 1,3,7,14,30,an 60 days after hospital visit~3. Text messaging support: patients will be registered in NCI's Smokefree TXT while in the hospital and will receive multiple daily messages, designed for someone who has already quit~4. Caregiver support: 10 minute training session to the caregiver on how to help patient prevent relapse by increasing self efficacy, maintaining motivation and dealing with high risk situations
Study NCT03673228 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment Counseling
Description: Participants will receive two 10 minute counseling calls from the staff of the preoperative counseling program during the first month after the hospital discharge
Study NCT04430582 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: ECG will take place during screening visit.
Study NCT01721980 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study NCT04304209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watch and wait
Description: Watch and wait for cCR patients after neoadjuvant treatment
Study NCT04304209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Watch and wait
Description: Watch and wait for cCR patients after neoadjuvant treatment
Study NCT03480880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral Index
Description: Thiopentone was administered in 50 mg boluses during induction of anaesthesia, until reduction of Bispectral Index value to less than 50, and total dose of thiopentone recorded.
Study NCT03262103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intratumoral (IT) Poly ICLC 0.5 mg
Description: 0.5 mg IT once/week (week 1)
Study NCT03262103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intratumoral (IT) Poly ICLC 1.0 mg
Description: 1.0 mg IT once/week (week 1)
Study NCT03262103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) Poly ICLC
Description: 1 mg IM twice weekly (weeks 3-6)
Study NCT03262103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: as per standard care
Study NCT02680444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Administered Mindful-Reappraisal Exercise
Description: Combining the practice of mindful acceptance of negative events combined with a reappraisal of the event by examining its positive aspects.
Study NCT02680444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Administered Reappraisal-Only Exercise
Description: A reappraisal of daily negative events by examining the positive aspects.
Study NCT02680444 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Administered Event Recall Exercise
Description: Recall a negative event that took place that day.
Study NCT01214590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VascuActive device
Description: self treatment by the patient, for 4 weeks, 3 sessions per day, approximately 30 minutes per session
Study NCT02464254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity plus positive affect
Description: Subjects will be randomized to a physical activity goal and will receive the positive affect component.
Study NCT02464254 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity plus education
Description: Subjects will be randomized to a physical activity goal and will receive the educational component.
Study NCT02464254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity plus education
Description: Subjects will be randomized to a physical activity goal and will receive the educational component.
Study NCT05779358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expectancy and gluten
Description: Effect of expectancy to receive gluten and/or actual gluten intake
Study NCT05779358 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Expectancy and gluten
Description: Effect of expectancy to receive gluten and/or actual gluten intake
Study NCT03131895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg dexlansoprazole capsules manufactured at TOB
Description: Dexlansoprazole delayed-release.
Study NCT03131895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg dexlansoprazole capsules manufactured at TPC
Description: Dexlansoprazole delayed-release.
Study NCT03131895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg dexlansoprazole capsules manufactured at TOB
Description: Dexlansoprazole delayed-release.
Study NCT03131895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg dexlansoprazole capsules manufactured at TPC
Description: Dexlansoprazole delayed-release.
Study NCT05028855 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral autoregulation assessment
Description: Cerebral autoregulation assessment will be conducted by specialized neurovascular ultrasound doctors during 0-3 and 10-30 days after stroke onset.The recorded data will be stored for further cerebral autoregulation analysis.
Study NCT00824070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifloxacin hydrochloride
Description: Instill besifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
Study NCT00824070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin hydrochloride
Description: Instill moxifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
Study NCT04571294 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: removal of para-aortic lymphnodes (PALN)
Description: During pancreaticoduodenectomy, para-aortic lymphnodes (PALN) will be removed for the surgeon
Study NCT02927210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethandrolone Undecanoate
Description: Single doses of DMAU in castor oil/benzyl benzoate injections intramuscularly (IM) (80 mg, 240 mg, 480 mg, and 800 mg) or administered subcutaneously (SC) (50 mg, 100 mg and 200 mg).
Study NCT02927210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injections that look like the DMAU injections but with no active ingredients
Study NCT02318420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The PartoMa intervention
Description: WHO partogram, locally developed and achievable labour management guidelines (PartoMa guidelines), continual in-house training
Study NCT03614039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Symbiter Forte
Description: Symbiter Forte which contains combination of smectite gel (250 mg), and biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g)
Study NCT03614039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03932045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYB Filler (SF-01)
Description: Apply up to 1.0 ml of the test device (SF-01) and the contrast device (Ellansé M) to both sides of the nasolabial fold.
Study NCT03932045 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ellansé M
Description: Apply up to 1.0 ml of the test device (SF-01) and the contrast device (Ellansé M) to both sides of the nasolabial fold.
Study NCT03270254 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: light activated dye photodynamic therapy (PDT)
Description: light activated dye photodynamic therapy-PDT to periodontal pockets
Study NCT02658656 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReWalk 6.0
Description: Exoskeletal Assisted Walking Device
Study NCT02558946 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Muscle Physical Therapy
Description: The treatment group will receive pelvic floor muscle training through a course of three one-hour sessions with a trained pelvic floor physical therapist in addition to the current standard information from their surgeon. The physical therapy sessions will be conducted at 1-6 weeks preoperative, 1 week postoperative, and 4-6 weeks postoperative and will be coordinated with surgeon appointments to minimize any inconvenience and travel time.
Study NCT02558946 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: At the cancer consultation visit, subjects will be educated by the urologist or urology team member regarding surgical and postoperative expectations. At this time, subjects will be provided verbal instruction and written information regarding Kegel exercises. Subjects in the control group may decide the duration and frequency of home exercise performance.
Study NCT04164667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental and physical (MAP) training intervention
Description: In this study, the MAP intervention consisted of two MAP training sessions and one health coaching session per week for eight weeks. Both groups received the same MAP intervention with the exception of the delivery format (directed versus self-guided).~Each MAP training session included 30 minutes of guided meditation and 30 minutes of moderate-to-vigorous aerobic exercise.
Study NCT04164667 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental and physical (MAP) training intervention
Description: In this study, the MAP intervention consisted of two MAP training sessions and one health coaching session per week for eight weeks. Both groups received the same MAP intervention with the exception of the delivery format (directed versus self-guided).~Each MAP training session included 30 minutes of guided meditation and 30 minutes of moderate-to-vigorous aerobic exercise.
Study NCT00503789 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fecal bacteria analysis
Description: ad lib feeding
Study NCT00503789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fecal bacteria analysis
Description: ad lib feeding
Study NCT00503789 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: fecal bacteria analysis
Description: ad lib feeding
Study NCT02662309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPDL3280A
Description: Intravenous infusion
Study NCT00824070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gatifloxacin
Description: Instill gatifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
Study NCT02723318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Coaching
Description: One-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
Study NCT02723318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to Referrals to Social Services
Study NCT02723318 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Access to Referrals to Social Services
Study NCT00249288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folate
Description: Folic acid taken as 2, 1mg capsule daily for 12 weeks
Study NCT00249288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken as 2, 1mg capsule daily for 12 weeks
Study NCT03024580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate 160Mg Tablet
Description: Megestrol acetate 160 mg PO daily
Study NCT03024580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole 1Mg Tablet
Description: Anastrozole 1 mg PO daily OR
Study NCT02000388 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ketorolac Tromethamine
Study NCT03673228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: Patients in both arms will be encouraged to receive NRT
Study NCT03673228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Description: Patients in both arms will be encouraged to receive NRT
Study NCT01558375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water for injection
Description: Placebo syringes will contain 0.67ml of sterile water for injection. This will be injecteda daily for 12 weeks.
Study NCT01558375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra will be supplied in single use pre-filed glass syringes with 27-gauge needles. Anakinra syringe will contain 100mg of anakinra at a volume of 0.67 ml. This will be injected subcutaneously daily for 12 weeks.
Study NCT03822819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic cocktail capsules
Description: Daily uptake of probiotic cocktail for three weeks
Study NCT03822819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsules
Description: Daily uptake of placebo capsule for three weeks
Study NCT01853085 — intervention group
Intervention type: DRUG
Intervention: Bimatoprost Ophthalmic Solution
Description: Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan® UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks.
Study NCT04480580 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 Ab
Description: Patient test for specific antibodies for SARS-CoV-2
Study NCT02443129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRI-1 Swept source OCT, Atlantis, Topcon
Description: Fundus imaging
Study NCT02000388 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Study NCT01573663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol and Levodropropizine
Description: Ambroxol HCl 30mg \& Levodropropizine 60mg, PO, Single dose
Study NCT01573663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambroxol
Description: Ambroxol HCl 30mg, PO, single dose